Hopkins and colleagues from Emergent BioSolutions identify several issues with our model for responding to a small scale anthrax attack.1 They are concerned that our model of preattack vaccination denied unvaccinated workers postattack antibiotics, that we underestimated vaccine efficacy, and that our 10-year time horizon was inadequate. They argue that these deficits produced an erroneous effectiveness assessment of preattack vaccination. Furthermore, they suggest we overestimated vaccine administration cost and excluded costs of cleanup and work force displacement inflating total cost of a preattack vaccination strategy. Lastly, they were concerned we had not stratified exposure risk among workers within the USPS.
Schmitt BP, Dobrez D, Kyriacou DN, Parada J. Preattack Vaccination Against Anthrax May Be Cost-effective in Certain Populations—Reply. Arch Intern Med. 2008;168(1):115. doi:10.1001/archinternmed.2007.21
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: